2023
Yuly P. Mendoza, Mohamed Shengir, Jaime Bosch, Giada Sebastiani, Annalisa Berzigotti. (2022). FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology. Volume 20(Issue 10):Pages 2396-2398, October 2022.
Mohamed Shengir, Carine Fillebeen, John Wagner, Agnihotram V. Ramanakumar, Mohammed Kaouache, Marina B. Klein, Kostas Pantopoulos, Giada Sebastiani. Increased Serum Fibroblast Growth Factor 23 Predicts Mortality in People With HIV/HCV Coinfection. Journal of Acquired Immune Deficiency Syndromes (JAIDS). Volume 94(Issue 3): Pages 273 - 279, November 2023.
Atif J, Udhesister S, Abdelnabi M, D'Souza S, Hung J, Edgar R, Gobran S, Gomez-Escobar E, Greenwald Z, Gallardo-Flores C, Fontaine G, Jeong D, Lanìece-Delaunay C, Lawton D, Makuza J, Masterman C, Marathe G, Mortazhejri S, Li J, Palmer M, Passos-Castilho A, Sag M, Shengir M, Wallance H, Mendlowitz AB. Impacts of the COVID-19 pandemic on Hepatitis C elimination in Canada, and where do we go from here? Canadian Liver Journal. Nov 2022;5(4):441-444.
Mendlowitz AB, Bremner KE, Krahn M, Walker JD, Wong WWL, Sander B, Jones L, Isaranuwatchai W, Feld JJ. Characterizing the cascade of care for hepatitis C virus infection among Status First Nations peoples in Ontario: a retrospective cohort study. CMAJ. 2023 Apr 11;195(14):E499-E512.
Mandel E, Biondi MJ, Mendlowitz AB, Maheandiranm M, Hollingdrake E, Vanderhoff, A, Wolfson-Stofko, B, Capraru C, Feld JJ, Logan R. Evaluation of hepatitis C screening and treatment among psychiatry inpatients. Journal of Clinical Psychiatry. 2023 Jul 31; 84(5):22m14623.
Bilinski A, Slimovitch R, Mendlowitz AB, Feld JJ, Salomon JA. First Do No Harm? Modeling risks and benefits of challenge trials for hepatitis C vaccine development. 2023 Aug 14; 77:S231-S237.
Mendlowitz AB, Mandel E, Capraru C, Hansen BE, Wong D, Feld JJ, Janssen HLA, Yim C. Factors associated with knowledge and awareness of Hepatitis B in individuals of Chinese descent: Results from a mass point of care testing and outreach campaign in Toronto, Canada. 2023. Canadian Liver Journal. (Accepted)
Zeitouny S, Cheung D, Bremner KE, Pataky R, Pequeno P, Matelski J, Peacock S, Del Giudice E, Lapointe-Shaw L, Tomlinson G, Mendlowitz AB, Mulder C, Tsui T, Perlis N, Walker J, Sander B, Wong WWL, Krahn M, Kulkarni G. The impact of the early COVID-19 pandemic on health care system resource use and costs in two provinces in Canada: An interrupted time series analysis. 2023 Sept 8. PLOS One.
Fattouh R, Boissinot K, Jeong E, Mendlowitz AB, Sjaarda CP, Wong H, Kozak R, Sheth PM, Matukas LM. Evaluation of Five PCR Assays for the Detection of Monkeypox Virus. 2023. Journal of Infectious Diseases (Accepted)
Mandel, E., Underwood, K., Masterman, C., Kozak, R. A., Dale, C. H., Hassall, M., ... & Biondi, M. J. (2023). Province-to-province variability in hepatitis C testing, care, and treatment across Canada. Canadian Liver Journal, 6(2), 234-248.
Crespi, A., Van Uum, R., Lathouris, H., Masterman, C., Muncaster, K., Gaete, K., ... & Biondi, M. J. (2023). Increasing linkage to hepatitis C care following trauma‐informed rehabilitation: An education and quality improvement project among women. Drug and Alcohol Review.
Jeong D*, Wong S, Karim ME, Manges AM, Makuza JD, Bartlett SR, Velásquez García HA, Luster D,
Adu PA, Binka M, Yu A, Alvarez M, Krajden M, Janjua NZ. Treatment of HCV with direct-acting
antivirals on reducing mortality related to extrahepatic manifestations: a large population-based study in
British Columbia, Canada. Lancet Regional Health - Americas. 2024/01
Binka M, Adu PA, Jeong D*, Vadlamudi NK, Velásquez García HA, Mahmood B, Buller-Taylor T,
Otterstatter M, Janjua NZ. The Impact of Mask Mandates on Face Mask Use During the COVID-19
Pandemic: Longitudinal Survey Study. JMIR Public Health and Surveillance. 9(1): e42616. 2023/11
Passos-Castilho AM, Persaud Udhesister ST, Fontaine G, Jeong D*, Dickie M, Lund C, Russell R, Kronfli
N. The 11th Canadian Symposium on Hepatitis C Virus:‘Getting back on track towards hepatitis C
elimination’. Canadian Liver Journal. 6(1): 56–69. 2023/02
Makuza JD, Jeong D*, Binka M, Adu PA, Cua G, Yu A, Velásquez García HA, Alvarez M, Wong S, Bartlett
S, Karim ME, Yoshida EM, Ramji A, Krajden M, Janjua NZ. Impact of Hepatitis B Virus Infection,
Non-alcoholic Fatty Liver Disease, and Hepatitis C Virus Co-infection on Liver-Related Death among
People Tested for Hepatitis B Virus in British Columbia. Viruses. 14(11): 2579. 2022/11
Atif J, Persaud Udhesister ST, Abdelnabi MN, D’Souza S, Hung JH, Edgar RD, Gobran ST, Gomez-
Escobar E, Greenwald ZR, Gallardo-Flores CE, Fontaine G, Jeong D*, Lanièce-Delaunay C, Lawton D,
Makuza JD, Masterman C, Marathe G, Mortazhejri S, Li J, Palmer M, Passos-Castilho AM, Sag M, Shengir
M, Wallace HL, Mendlowitz AB. Impacts of the COVID-19 pandemic on hepatitis C elimination in
Canada: Where do we go from here? Canadian Liver Journal. 5(4): 441-444. 2022/11
Lettner, Bernadette, Kate Mason, Zoë R. Greenwald, Jennifer Broad, Erin Mandel, Jordan J. Feld, and Jeff Powis. "Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study." The Lancet Regional Health–Americas 22 (2023).
| Greenwald, Zoë R., Zachary Bouck, Elizabeth McLean, Kate Mason, Bernadette Lettner, Jennifer Broad, Zoë Dodd, Tanner Nassau, Ayden I. Scheim, and Dan Werb. "Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: A cross‐sectional analysis." Journal of Viral Hepatitis 30, no. 2 (2023): 160-171. |
Atif J, Udhesister STP, Abdelnabi MN, D’Souza S, Hung JH, Edgar RD, Gobran, ST, Gomez-Escobar, E, Greenwald, ZR, Gallardo-Flores, CE, Fontaine, G, Jeong, D, Lanice-Delaunay, C, Lawton, D, Makuza, JD, Masterman, C, Marathe, G, Mortazhejri, S, Li, J, Palmer
Banting H, Goode I, Gallardo-Flores CE, Colpitts CC and Saavedra CE (2023) Electromagnetic deactivation spectroscopy of human coronavirus 229E. Scientific Reports 13: 8886
Mamatis JE, Gallardo-Flores CE, Sangwan U, Tooley TH, Walsh T and Colpitts CC (2023) Induction of antiviral gene expression by cyclosporine A, but not inhibition of cyclophilin A or B, contributes to its restriction of human coronavirus 229E infection in a lung epithelial cell line. Antiviral Research 219: 105730
Rheault M, Cousineau SE, Fox DR, Abram QH, Sagan SM. Elucidating the Distinct Contributions of miR-122 in the HCV Life Cycle Reveals Insights into Virion Assembly. Nucleic Acids Research.
2022
Wallace, H. L., & Russell, R. S. (2022). Promiscuous Inflammasomes: The False Dichotomy of RNA/DNA Virus-Induced Inflammasome Activation and Pyroptosis. Viruses, 14(10), 2113.
Wallace, H. L., Wang, L., Gardner, C. L., Corkum, C. P., Grant, M. D., Hirasawa, K., & Russell, R. S. (2022). Crosstalk between pyroptosis and apoptosis in hepatitis C virus-induced cell death. Frontiers in immunology, 144.
Sarvestany SS, Kwong JC, Azhie A, Dong V, Cerocchi O, Ali AF, Karnam RS, Kuriry H, Shengir M, Candido E, Duchen R, Sebastiani G, Patel K, Goldenberg A, Bhat M. Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study. Lancet Digit Health. 2022 Mar;4(3):e188-e199.
Cousineau SE, Rheault M, Sagan SM. Poly(rC)-binding protein 1 limits hepatitis C virion assembly and secretion. Viruses. 14(2):291, 2022 January
Panigrahi, M., Palmer, M.A., and Wilson, J.A. Enhanced virus translation enables miR-122-independent Hepatitis C Virus propagation. Journal of Virology.
Panigrahi, M., Palmer, M.A., and Wilson, J.A. MicroRNA-122 Regulation of HCV Infections: Insights from Studies of miR-122-Independent Replication. Pathogens. 11(9): 1005, 2022 August.
Darwish I, Harrison LB, Passos-Castilho AM, Labbé AC, Barkati S, Luong ML, Kong LY, Tutt-Guérette MA, Kierans J, Rousseau C, Benedetti A, Azoulay L, Greenaway C. In-hospital outcomes of SARS-CoV-2-infected health care workers in the COVID-19 pandemic first wave, Quebec, Canada. PLoS One. 2022 Aug 24;17(8):e0272953.
Passos-Castilho AM, Labbé AC, Barkati S, Luong ML, Dagher O, Maynard N, Tutt-Guérette MA, Kierans J, Rousseau C, Benedetti A, Azoulay L, Greenaway C. Outcomes of hospitalized COVID-19 patients in Canada: impact of ethnicity, migration status and country of birth. J Travel Med. 2022 Sep 17;29(6):taac041.
Mazouz S, Salinas E, Bédard N, Filali A, Khedr O, Abdel-Hakeem M, Siddique A, Bruneau J, Grakoui A and Shoukry NH.
Differential Immune Transcriptomic Profiles between Vaccinated and Resolved HCV Reinfected Subjects. PloS Pathogen
Molina MF, Abdelnabi MN, Mazouz S, Villafranca-Baughman D, Quoc-Huy Trinh V, Muhammad S, Bédard N, Osorio Laverde D, Hassan GS, Di Polo A, Shoukry NH.
Distinct spatial distribution and roles of Kupffer cells and monocyte-derived macrophages in mouse acute liver injury. Frontiers in Immunology. September 2022.
Marathe G., Moodie E.M., Brouillette M-J., Lanièce Delaunay C., Cooper C., Hull M., Martel-Laferrière V., Walmsley S., Cox J., Klein M.B.; Canadian Co-Infection Cohort. Predicting the presence of depressive symptoms in the HIV-HCV co-infected population in Canada using supervised machine learning.
Lanièce Delaunay C., Maheu-Giroux M., Marathe G., Saeed S., Martel-Laferrière V., Cooper C., Walmsley S., Cox J., Wong A., Klein M. B., Gaps in Hepatitis C virus prevention and care for HIV-Hepatitis C virus co-infected people who inject drugs in Canada. International Journal of Drug Policy. February 2022.
Marathe G, Moodie EE, Brouillette MJ, et al. Impact of HCV cure on depressive symptoms in the HIV-HCV co-infected population in Canada. Clinical Infectious Diseases. Published online on July 5, 2022
Marathe, G., Moodie, E. E. M., Brouillette, M.-J., Cox, J., Delaunay, C. L., Cooper, C., Hull, M., Gill, J., Walmsley, S., Pick, N., & Klein, M. B. Depressive symptoms are no longer a barrier to HCV treatment initiation in the HIV–HCV co-infected population in Canada. Antiviral Therapy, 27(1), February 15, 2022
Gomes, T*, Kolla, G*, McCormack, D, Sereda, A, Kitchen, S, Antoniou, T. Clinical outcomes and healthcare costs among people entering a safer opioid supply program in Ontario. CMAJ: Canadian Medical Association Journal. 2022 September 19; 194: E1233-42.
Kolla G, Touesnard N, Gomes T. Addressing the overdose crisis in North America with bold action. Addiction; 117 (5): 1194-1196.
Gomes, T., Kitchen, S., Campbell, T., Murray, R., Leece, P., & Kolla, G. Responding to Ontario’s Overdose Crisis in the Context of the COVID-19 Pandemic. Healthcare Quarterly, 25(2), 7–12.
Kenny, K, Kolla, G, Firestone, M, Bannerman, M, Greig, S, Flores, B.F., Dodd, Z., Strike, C., Bayoumi, A. Frequency of fatal and non-fatal overdoses and grief reactions among people who inject drugs: An unexplored dimension of the opioid overdose crisis.
Glegg, S, McCrae, K, Kolla, G, Touesnard, N, Turnbull, J, Brothers, T, Brar, R, Sutherland, C, Le Foll, B, Sereda, A, Goyer, ME, Rai, N, Berstein, S, Fairbairn, N. “COVID just kind of opened a can of whoop-ass”: The rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. International Journal of Drug Policy, 106, 103742.
Mitra, S, Kolla, G, Bardwell, G, Wang, R, Sniderman, R, Mason, K, Werb, D, Scheim, A. Requiring help injecting among people who inject drugs in Toronto, Canada: Characterising the need to address sociodemographic disparities and substance-use specific patterns
Nassau, T, Kolla, G, Mason, K, Hopkins, S, Tookey, P, McLean, E, Werb, D, Scheim, A. Service utilization patterns and characteristics among clients of integrated supervised consumption sites in Toronto, Canada. Harm Reduction Journal
Young S, Kolla G, McCormack D, Campbell T, Leece P, Strike C, Srivastava A, Antoniou T, Bayoumi A, Gomes T. Characterizing safer supply prescribing of immediate release hydromorphone for individuals with opioid use disorder across Ontario, Canada. International Journal of Drug Policy, 2022; 102: 103601.
Gomes, T, Tailor, L, Kitchen, S, Men, S, Murray, R, Bayoumi, A, Campbell, T, Young, S, Kolla, G. Trends in hospitalizations for infective endocarditis and invasive infections among people with an opioid use disorder in Ontario, Canada. Journal of Addiction Medicine.
Greenwald ZR, Bouck Z, McLean E, Mason K, Lettner B, Broad J, Dodd Z, Nassau T, Scheim A, Werb D. Integrated Supervised Consumption Services and Hepatitis C Testing and Treatment Among People Who Inject Drugs in Toronto: A Cross-Sectional Analysis. Journal of Viral Hepatitis. 2022
Saavedra Ruiz, A.*, Fontaine, G.*, Patey, A. M., Grimshaw, J., Presseau, J., Cox, J., Dussault, C. & Kronfli, N. (2022). Identifying barriers and enablers to opt-out hepatitis C virus screening in provincial prisons in Quebec, Canada: A multilevel, multi-theory informed qualitative study with correctional and healthcare professional stakeholders. International Journal of Drug Policy, 109, 103837.
Passos-Castilho, A. M., Udhesister, S. T. P., Fontaine, G., Jeong, D., Dickie, M., Lund, C., Russell, R., Kronfli, N., on behalf of the Canadian Network on Hepatitis C (CanHepC). (2022). The 11th Canadian Symposium on Hepatitis C Virus: “Getting back on track towards hepatitis C elimination”. Canadian Liver Journal.
Cunningham, E. B., Wheeler, A., Hajarizadeh, B., French, C., Roche, R., Marshall, A., Fontaine, G., Conway, A., Bajis, S., Valencia, B. M., Presseau, J., Ward, J. W., Degenhardt, L., Dore, G. J., Hickman, M., Vickerman, P., & Grebely, J. (2022). Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. International Journal of Drug Policy.
Flores Molina M, Abdelnabi MN, Mazouz S, et al. Distinct spatial distribution and roles of Kupffer cells and monocyte-derived macrophages in mouse acute liver injury. Front Immunol 2022;13:994480.
Abdelnabi MN, Flores Molina M, Soucy G, et al. Sex-Dependent Hepatoprotective Role of IL-22 Receptor Signaling in Non-Alcoholic Fatty Liver Disease-Related Fibrosis. Cell Mol Gastroenterol Hepatol 2022;14:1269-1294.
Atif J, Udhesister STP, Abdelnabi MN, et al. Impacts of the COVID-19 pandemic on hepatitis C elimination in Canada: Where do we go from here? CanLivJ. Published online October 4, 2022.
Arif AA, Huang Y-H, Freeman SA, et al. Inflammation-Induced Metastatic Colonization of the Lung Is Facilitated by Hepatocyte Growth Factor-Secreting Monocyte-Derived Macrophages. Mol Cancer Res. 2021;19(12):2096-2109.
Atif J, Thoeni C, Bader GD, McGilvray ID, MacParland SA. Unraveling the complexity of liver disease one cell at a time. Semin Liver Dis. 2022;42(3):250-270.
Andrews TS, Atif J, Liu JC, et al. Single-Cell, Single-Nucleus, and Spatial RNA Sequencing of the Human Liver Identifies Cholangiocyte and Mesenchymal Heterogeneity. Hepatol Commun. 2022;6(4):821-840.
Hannah L Wallace*, Lingyan Wang*, Cassandra L. Gardner, Christopher P Corkum, Michael D Grant, Kensuke Hirasawa, and Rodney S Russell (*Equal Contribution). Crosstalk Between Pyroptosis and Apoptosis in Hepatitis C Virus-induced Cell Death (In Press; 2022, Frontiers in Immunology)
Sophie E. Cousineau, Marylin Rheault, Selena M. Sagan. Poly(rC)-binding protein 1 limits hepatitis C virus virion assembly and secretion. Viruses, 2022
2021
Mazouz S, Boisvert M, Abdel-Hakeem MS, Khedr O, Bruneau J, Shoukry NH. Expansion of Unique Hepatitis C Virus-Specific Public CD8+T Cell Clonotypes during Acute Infection and Reinfection. J Immunol. 2021 Aug 15;207(4):1180-1193. doi: 10.4049/jimmunol.2001386. Epub 2021 Aug 2.
Heidebrecht L, Iyer S, Laframboise SL, Madampage C, King A. Every One of Us Is a Strand in That Basket": Weaving Together Stories of Indigenous Wellness and Resilience From the Perspective of Those With Lived and Living Experience With HIV/Hepatitis C Virus. J Assoc Nurses AIDS Care. 2021 Jul 20.
Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, Lloyd AR; International Network on Health and Hepatitis in Substance Users–Prisons Network. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol. 2021 May;6(5):391-400.
Léa Duchesne, Camille Dussault, Arnaud Godin, Mathieu Maheu-Giroux, Nadine Kronfli. Implementing opt-out hepatitis C virus (HCV) screening in Canadian provincial prisons: A model-based cost-effectiveness analysis. International Journal of Drug Policy. Volume 96, October 2021, 103345
Charlotte Lanièce Delaunay, Arnaud Godin, Nadine Kronfli, Dimitra Panagiotoglou, Joseph Cox, Michel Alary, Marina B. Klein, Mathieu Maheu-Giroux. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030? International Journal of Drug Policy. Volume 96, October 2021, 103343
Bartlett SR, Wong S, Yu A, Pearce M, MacIsaac J, Nouch S, Adu P, Wilton J, Samji H, Clementi E, Velasquez H, Jeong D, Binka M, Alvarez M, Wong J, Buxton J, Krajden M, Janjua NZ. The impact of current opioid agonist therapy on hepatitis C virus treatment initiation among people who use drugs from in the DAA era: A population-based study. Clin Infect Dis. 2021 Jun 14:ciab546.
Andreea Adelina Artenie, Emmanuel Fortier, Marie-Pierre Sylvestre, Stine Bordier Høj, Nanor Minoyan, Lise Gauvin, Didier Jutras-Aswad, Julie Bruneau. Socioeconomic stability is associated with lower injection frequency among people with distinct trajectories of injection drug use. International Journal of Drug Policy. Volume 94, 2021, 103205,
Andrews TS, Atif J, Liu JC, Perciani CT, Ma XZ, Thoeni C, Slyper M, Eraslan G, Segerstolpe A, Manuel J, Chung S, Winter E, Cirlan I, Khuu N, Fischer S, Rozenblatt-Rosen O, Regev A, McGilvray ID, Bader GD, MacParland SA. Single-Cell, Single-Nucleus, and Spatial RNA Sequencing of the Human Liver Identifies Cholangiocyte and Mesenchymal Heterogeneity. Hepatol Commun. 2021 Nov 18.
Jiafeng Li, BSc1,2,3, Julia L Casey, MSc4,5, Zoë R Greenwald, MSc6, Abdool S Yasseen III, PhD6, Melisa Dickie, MHSc7, Jordan J Feld, MD4,5,8, Curtis L Cooper, MD, FRCPC3,9,10,11, and Angela M Crawley on behalf of the Canadian Network on Hepatitis C (CanHepC), PhD. The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination
Fortier, E., S. B. Høj, M. P. Sylvestre, A. A. Artenie, N. Minoyan, D. Jutras-Aswad, J. Grebely, and J. Bruneau. Injecting Frequency Trajectories and Hepatitis C Virus Acquisition: Findings from a Cohort of People Who Inject Drugs in Montréal, Canada. Int J Drug Policy (Sep 10 2021): 103439.
Abdel-Hakeem, Mohamed S., Sasikanth Manne, Jean-Christophe Beltra, Erietta Stelekati, Zeyu Chen, Kito Nzingha, Mohammed-Alkhatim Ali, et al. Epigenetic Scarring of Exhausted T Cells Hinders Memory Differentiation Upon Eliminating Chronic Antigenic Stimulation. Nature Immunology 22, no. 8 (2021/08/01 2021): 1008-19.
2020
Kunden RD, Ghezelbash S, Khan JQ, Wilson JA. Location specific annealing of miR-122 and other small RNAs defines an Hepatitis C Virus 5' UTR regulatory element with distinct impacts on virus translation and genome stability. Nucleic Acids Res. 2020 Sep 18;48(16):9235-9249.
Turton, K. L., V. Meier-Stephenson, M. D. Badmalia, C. S. Coffin, and T. R. Patel. Host Transcription Factors in Hepatitis B Virus Rna Synthesis. Viruses 12, no. 2 (Jan 30 2020).
Shaw, T. A., C. J. Ablenas, G. F. Desrochers, M. H. Powdrill, D. A. Bilodeau, J. F. Vincent-Rocan, M. Niu, et al. A Bifunctional Nucleoside Probe for the Inhibition of the Human Immunodeficiency Virus-Type 1 Reverse Transcriptase. Bioconjug Chem (Apr 27 2020).
Pechlivanoglou, et al. A Systematic Review and Meta-Analysis of Health Utilities in Patients with Chronic Hepatitis C. Value Health 23, no. 1 (Jan 2020): 127-37.
Picard, J., B. Jacka, S. Hoj, E. Laverdiere, J. Cox, E. Roy, and J. Bruneau. Real-World Eligibility for Hiv Pre-Exposure Prophylaxis among People Who Inject Drugs. AIDS Behav (Jan 29 2020).
Mesidor, M., M. P. Sylvestre, N. Minoyan, and J. O'Loughlin. Cigarette Smoking and Nicotine Dependence Trajectories among Incident Adolescent Smokers. Nicotine Tob Res (Jan 23 2020).
Mendlowitz, A. B., D. Naimark, W. W. L. Wong, C. Capraru, J. J. Feld, W. Isaranuwatchai, and M. Krahn. The Emergency Department as a Setting-Specific Opportunity for Population-Based Hepatitis C Screening: An Economic Evaluation. Liver Int (Apr 8 2020).
Marshall, A. D., J. Grebely, G. J. Dore, and C. Treloar. Barriers and Facilitators to Engaging in Hepatitis C Management and Daa Therapy among General Practitioners and Drug and Alcohol Specialists-the Practitioner Experience. Drug Alcohol Depend 206 (Jan 1 2020): 107705.
Liu, L. Y., X. Z. Ma, B. Ouyang, D. P. Ings, S. Marwah, J. Liu, A. Y. Chen, et al. Nanoparticle Uptake in a Spontaneous and Immunocompetent Woodchuck Liver Cancer Model. ACS Nano 14, no. 4 (Apr 28 2020): 4698-715.
Janjua, N. Z., S. Wong, M. Darvishian, Z. A. Butt, A. Yu, M. Binka, M. Alvarez, et al. The Impact of Svr from Direct-Acting Antiviral- and Interferon-Based Treatments for Hcv on Hepatocellular Carcinoma Risk. J Viral Hepat (Mar 18 2020).
Jacka, B., S. Larney, L. Degenhardt, N. Janjua, S. Hoj, M. Krajden, J. Grebely, and J. Bruneau. Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent Hiv and Hepatitis C Virus Infection among People Who Inject Drugs in Canada. Am J Public Health 110, no. 1 (Jan 2020): 45-50.
Godin, A., N. Kronfli, J. Cox, M. Alary, and M. Maheu-Giroux. The Role of Prison-Based Interventions for Hepatitis C Virus (Hcv) Micro-Elimination among People Who Inject Drugs in Montreal, Canada. Int J Drug Policy (Apr 8 2020): 102738.
Gemmill, D., S. D'Souza, V. Meier-Stephenson, and T. R. Patel. Current Approaches for Rna-Labelling to Identify Rna-Binding Proteins. Biochem Cell Biol 98, no. 1 (Feb 2020): 31-41.
Fortier, E., M. P. Sylvestre, A. A. Artenie, N. Minoyan, D. Jutras-Aswad, E. Roy, J. Grebely, and J. Bruneau. Associations between Housing Stability and Injecting Frequency Fluctuations: Findings from a Cohort of People Who Inject Drugs in Montreal, Canada. Drug Alcohol Depend 206 (Jan 1 2020): 107744.
Flores Molina, M., T. Fabre, A. Cleret-Buhot, G. Soucy, L. Meunier, M. N. Abdelnabi, N. Belforte, S. Turcotte, and N. H. Shoukry. Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment. J Vis Exp, no. 157 (Mar 25 2020).
Erman, A., W. W. L. Wong, J. J. Feld, P. Grootendorst, and M. D. Krahn. The Health Impact of Delaying Direct-Acting Antiviral Treatment for Chronic Hepatitis C: A Decision-Analytic Approach. Liver Int 40, no. 1 (Jan 2020): 51-59.
Darvishian, M., S. Wong, M. Binka, A. Yu, A. Ramji, E. M. Yoshida, J. Wong, et al. Loss to Follow-Up: A Significant Barrier in the Treatment Cascade with Direct-Acting Therapies. J Viral Hepat 27, no. 3 (Mar 2020): 243-60.
Cousineau, Sophie E, Aysegul Erman, Lewis Liu, Sahar Saeed, Lorraine Fradette, Jordan J Feld, Jason Grebely, et al. The 8th Canadian Symposium on Hepatitis C Virus: “Improving Diagnosis and Linkage to Care”. Canadian Liver Journal 3, no. 1 (2020): 3-14.
Binka, M., N. Z. Janjua, J. Grebely, C. Estes, D. Schanzer, J. A. Kwon, N. H. Shoukry, et al. Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model. JAMA Netw Open 3, no. 5 (May 1 2020): e204192.
Bajis, S., J. Grebely, B. Hajarizadeh, T. Applegate, A. D. Marshall, M. Ellen Harrod, J. Byrne, et al. Hepatitis C Virus Testing, Liver Disease Assessment and Treatment Uptake among People Who Inject Drugs Pre- and Post-Universal Access to Direct-Acting Antiviral Treatment in Australia: The Liverlife Study. J Viral Hepat 27, no. 3 (Mar 2020): 281-93.
2019
Vranjkovic, A., F. Deonarine, S. Kaka, J. B. Angel, C. L. Cooper, and A. M. Crawley. Direct-Acting Antiviral Treatment of Hcv Infection Does Not Resolve the Dysfunction of Circulating Cd8(+) T-Cells in Advanced Liver Disease. Front Immunol 10 (2019): 1926
Tai, C. J., C. H. Liu, Y. C. Pan, S. H. Wong, C. J. Tai, C. D. Richardson, and L. T. Lin. Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells. Sci Rep 9, no. 1 (May 1 2019): 6767.
Singaravelu, R., N. Ahmed, C. Quan, P. Srinivasan, C. J. Ablenas, D. G. Roy, and J. P. Pezacki. A Conserved Mirna-183 Cluster Regulates the Innate Antiviral Response. J Biol Chem 294, no. 51 (Dec 20 2019): 19785-94.
Saeed, S., E. Strumpf, E. E. M. Moodie, L. Wong, J. Cox, S. Walmsley, M. Tyndall, et al. Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with Hiv. Clin Infect Dis (Aug 28 2019).
Rossi, C., D. Jeong, S. Wong, G. McKee, Z. A. Butt, J. Buxton, J. Wong, et al. Sustained Virological Response from Interferon-Based Hepatitis C Regimens Is Associated with Reduced Risk of Extrahepatic Manifestations. J Hepatol 71, no. 6 (Dec 2019): 1116-25.
Molina, M. F., M. N. Abdelnabi, T. Fabre, and N. H. Shoukry. Type 3 Cytokines in Liver Fibrosis and Liver Cancer. Cytokine 124 (Dec 2019): 154497.
Marshall, A. D., A. Madden, and C. Treloar. Enhancing Engagement in Hepatitis C Care among People Who Inject Drugs. Addiction 114, no. 12 (Dec 2019): 2104-06.
Makarenko, I., A. Artenie, S. Hoj, N. Minoyan, B. Jacka, G. Zang, G. Barlett, et al. Transitioning from Interferon-Based to Direct Antiviral Treatment Options: A Potential Shift in Barriers and Facilitators of Treatment Initiation among People Who Use Drugs? Int J Drug Policy 72 (Oct 2019): 69-76.
Leung, J., A. Peacock, S. Colledge, J. Grebely, E. B. Cunningham, M. Hickman, P. Vickerman, et al. A Global Meta-Analysis of the Prevalence of Hiv, Hepatitis C Virus, and Hepatitis B Virus among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators? J Infect Dis 220, no. 1 (Jun 5 2019): 78-90.
Kronfli, Nadine, Jane A Buxton, Lindsay Jennings, Fiona Kouyoumdjian, and Alexander Wong. Hepatitis C Virus (Hcv) Care in Canadian Correctional Facilities: Where are We and Where Do We Need to Be?. Canadian Liver Journal 2, no. 4 (2019): 171-83.
Krajden, M., D. A. Cook, S. Wong, A. Yu, Z. A. Butt, C. Rossi, M. Darvishian, et al. What Is Killing People with Hepatitis C Virus Infection? Analysis of a Population-Based Cohort in Canada. Int J Drug Policy 72 (Oct 2019): 114-22.
Kolla, G., and C. Strike. 'It's Too Much, I'm Getting Really Tired of It': Overdose Response and Structural Vulnerabilities among Harm Reduction Workers in Community Settings. Int J Drug Policy 74 (Dec 2019): 127-35.
Janjua, N. Z., M. Darvishian, S. Wong, A. Yu, C. Rossi, A. Ramji, E. M. Yoshida, et al. Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy. Hepatol Commun 3, no. 4 (Apr 2019): 478-92.
Jacka, B., E. Roy, S. Hoj, N. Minoyan, A. A. Artenie, G. Zang, D. Jutras-Aswad, and J. Bruneau. Sexual Behaviour as a Risk Factor for Hepatitis C Virus Infection among People Who Inject Drugs in Montreal, Canada. J Viral Hepat 26, no. 12 (Dec 2019): 1413-22.
Hoj, S. B., B. Jacka, N. Minoyan, A. A. Artenie, and J. Bruneau. Conceptualising Access in the Direct-Acting Antiviral Era: An Integrated Framework to Inform Research and Practice in Hcv Care for People Who Inject Drugs. Int J Drug Policy 72 (Oct 2019): 11-23.
Greenaway, Emma, Mia J Biondi, Jordan J Feld, and Simon C Ling. Hepatitis C Virus Infection in Mothers and Children. Canadian Liver Journal 2, no. 4 (2019): 210-24.
Grebely, J., S. Larney, A. Peacock, S. Colledge, J. Leung, M. Hickman, P. Vickerman, et al. Global, Regional, and Country-Level Estimates of Hepatitis C Infection among People Who Have Recently Injected Drugs. Addiction 114, no. 1 (Jan 2019): 150-66.
Fortier, E., A. A. Artenie, G. Zang, D. Jutras-Aswad, E. Roy, J. Grebely, and J. Bruneau. Short and Sporadic Injecting Cessation Episodes as Predictors of Incident Hepatitis C Virus Infection: Findings from a Cohort Study of People Who Inject Drugs in Montreal, Canada. Addiction 114, no. 8 (Aug 2019): 1495-503.
Erman, A., M. D. Krahn, T. Hansen, J. Wong, J. M. Bielecki, J. J. Feld, W. W. L. Wong, P. Grootendorst, and H. H. Thein. Estimation of Fibrosis Progression Rates for Chronic Hepatitis C: A Systematic Review and Meta-Analysis Update. BMJ Open 9, no. 11 (Nov 11 2019): e027491.
Biondi, Mia J, and Jordan J Feld. Hepatitis C Models of Care: Approaches to Elimination. Canadian Liver Journal 0, no. 0 (2019): 1-12.
Bernier, A., and S. M. Sagan. Beyond Sites 1 and 2, Mir-122 Target Sites in the Hcv Genome Have Negligible Contributions to Hcv Rna Accumulation in Cell Culture. J Gen Virol 100, no. 2 (Feb 2019): 217-26.
Bartlett, S. R., A. Yu, N. Chapinal, C. Rossi, Z. Butt, S. Wong, M. Darvishian, et al. The Population Level Care Cascade for Hepatitis C in British Columbia, Canada as of 2018: Impact of Direct Acting Antivirals. Liver Int 39, no. 12 (Dec 2019): 2261-72.
Artenie, A. A., N. Minoyan, B. Jacka, S. Hoj, D. Jutras-Aswad, E. Roy, L. Gauvin, G. Zang, and J. Bruneau. Opioid Agonist Treatment Dosage and Patient-Perceived Dosage Adequacy, and Risk of Hepatitis C Infection among People Who Inject Drugs. Cmaj 191, no. 17 (Apr 29 2019): E462-e68.
Artenie, A. A., E. B. Cunningham, G. J. Dore, B. Conway, O. Dalgard, J. Powis, P. Bruggmann, et al. Patterns of Drug, Alcohol Use and Injection Equipment Sharing among People with Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment with Direct-Acting Antiviral Therapies: An International Study. Clin Infect Dis (Jul 11 2019).
Ahmed, N., D. V. Foss, M. H. Powdrill, and J. P. Pezacki. Site-Specific Cross-Linking of a P19 Viral Suppressor of Rna Silencing Protein and Its Rna Targets Using an Expanded Genetic Code. Biochemistry 58, no. 33 (Aug 20 2019): 3520-26.
Ahmed, N., D. V. Foss, M. H. Powdrill, and J. P. Pezacki. Site-Specific Cross-Linking of a P19 Viral Suppressor of Rna Silencing Protein and Its Rna Targets Using an Expanded Genetic Code. Biochemistry 58, no. 33 (Aug 20 2019): 3520-26.
Ahmed, F., A. Ibrahim, C. L. Cooper, A. Kumar, and A. M. Crawley. Chronic Hepatitis C Virus Infection Impairs M1 Macrophage Differentiation and Contributes to Cd8(+) T-Cell Dysfunction. Cells 8, no. 4 (Apr 25 2019).
Ablenas, C. J., Y. Gidi, M. H. Powdrill, N. Ahmed, T. A. Shaw, M. Mesko, M. Gotte, G. Cosa, and J. P. Pezacki. Hepatitis C Virus Helicase Binding Activity Monitored through Site-Specific Labeling Using an Expanded Genetic Code. ACS Infect Dis 5, no. 12 (Dec 13 2019): 2118-26.
Abdel-Hakeem, M. S. Viruses Teaching Immunology: Role of Lcmv Model and Human Viral Infections in Immunological Discoveries. Viruses 11, no. 2 (Jan 27 2019).
2018
Wu, Q., Z. Li, and Q. Liu. An Important Role of Srebp-1 in Hbv and Hcv Co-Replication Inhibition by Pten. Virology 520 (Jul 2018): 94-102.
Wong, William WL, Alex Haines, Hooman Farhang Zangneh, and Hemant Shah. Can We Afford Not to Screen and Treat Hepatitis C Virus Infection in Canada?. Canadian Liver Journal 1, no. 2 (2018): 51-65.
Wong, Alexander, Cynthia Tsien, Sarah Mansour, and Curtis Cooper. Remaining Clinical Issues in Hepatitis C Treatment. Canadian Liver Journal 1, no. 2 (2018): 66-77.
van Buuren, N., T. L. Tellinghuisen, C. D. Richardson, and K. Kirkegaard. Transmission Genetics of Drug-Resistant Hepatitis C Virus. Elife 7 (Mar 28 2018).
van Buuren, N., and K. Kirkegaard. Detection and Differentiation of Multiple Viral Rnas Using Branched DNA Fish Coupled to Confocal Microscopy and Flow Cytometry. Bio Protoc 8, no. 20 (Oct 20 2018).
Smith, L. K., G. M. Boukhaled, S. A. Condotta, S. Mazouz, J. J. Guthmiller, R. Vijay, N. S. Butler, et al. Interleukin-10 Directly Inhibits Cd8(+) T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. Immunity 48, no. 2 (Feb 20 2018): 299-312.e5.
Singaravelu, R., C. Quan, M. H. Powdrill, T. A. Shaw, P. Srinivasan, R. K. Lyn, R. C. Alonzi, et al. Microrna-7 Mediates Cross-Talk between Metabolic Signaling Pathways in the Liver. Sci Rep 8, no. 1 (Jan 10 2018): 361.
Shoukry, Naglaa H, Jordan J Feld, and Jason Grebely. Hepatitis C: A Canadian Perspective. Canadian Liver Journal 1, no. 2 (2018): 1-3.
Shaw, T. A., R. Singaravelu, M. H. Powdrill, J. Nhan, N. Ahmed, D. Ozcelik, and J. P. Pezacki. Microrna-124 Regulates Fatty Acid and Triglyceride Homeostasis. iScience 10 (Dec 21 2018): 149-57.
Schanzer, D., L. Pogany, J. Aho, K. Tomas, M. Gale-Rowe, J. C. Kwong, N. Z. Janjua, and J. Feld. Impact of Availability of Direct-Acting Antivirals for Hepatitis C on Canadian Hospitalization Rates, 2012-2016. Can Commun Dis Rep 44, no. 7-8 (Jul 5 2018): 150-56.
Saeed, S., E. E. M. Moodie, E. Strumpf, J. Gill, A. Wong, C. Cooper, S. Walmsley, et al. Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life in Hiv/Hepatitis C Co-Infected Individuals. J Viral Hepat 25, no. 12 (Dec 2018): 1507-14.
Rossi, C., S. Saeed, J. Cox, M. L. Vachon, V. Martel-Laferriere, S. L. Walmsley, C. Cooper, et al. Hepatitis C Virus Cure Does Not Impact Kidney Function Decline in Hiv Co-Infected Patients. Aids 32, no. 6 (Mar 27 2018): 751-59.
Rossi, C., Z. A. Butt, S. Wong, J. A. Buxton, N. Islam, A. Yu, M. Darvishian, et al. Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort. J Hepatol 69, no. 5 (Nov 2018): 1007-14.
Rosenberg, B. R., M. Depla, C. A. Freije, D. Gaucher, S. Mazouz, M. Boisvert, N. Bedard, et al. Longitudinal Transcriptomic Characterization of the Immune Response to Acute Hepatitis C Virus Infection in Patients with Spontaneous Viral Clearance. PLoS Pathog 14, no. 9 (Sep 2018): e1007290.
Meier-Stephenson, V., W. T. R. Bremner, C. S. Dalton, G. van Marle, C. S. Coffin, and T. R. Patel. Comprehensive Analysis of Hepatitis B Virus Promoter Region Mutations. Viruses 10, no. 11 (Nov 1 2018).
McKee, G., Z. A. Butt, S. Wong, T. Salway, M. Gilbert, J. Wong, M. Alvarez, et al. Syndemic Characterization of Hcv, Hbv, and Hiv Co-Infections in a Large Population Based Cohort Study. EClinicalMedicine 4-5 (Oct-Nov 2018): 99-108.
Mazouz, Sabrina, Maude Boisvert, Naglaa H Shoukry, and Daniel Lamarre. Reversing Immune Dysfunction and Liver Damage after Direct-Acting Antiviral Treatment for Hepatitis C. Canadian Liver Journal 1, no. 2 (2018): 78-105.
Marshall, A. D., J. M. Pawlotsky, J. V. Lazarus, A. Aghemo, G. J. Dore, and J. Grebely. The Removal of Daa Restrictions in Europe - One Step Closer to Eliminating Hcv as a Major Public Health Threat. J Hepatol 69, no. 5 (Nov 2018): 1188-96.
Law, John LM, Mike Logan, Amir Landi, D Lorne Tyrrell, and Michael Houghton. Progress toward Approval of an Hcv Vaccine. Canadian Liver Journal 1, no. 3 (2018): 130-38.
Lamoury, F. M. J., S. Bajis, B. Hajarizadeh, A. D. Marshall, M. Martinello, E. Ivanova, B. Catlett, et al. Evaluation of the Xpert Hcv Viral Load Finger-Stick Point-of-Care Assay. J Infect Dis 217, no. 12 (May 25 2018): 1889-96.
Krajden, Mel, Darrel Cook, and Naveed Z Janjua. Contextualizing Canada’s Hepatitis C Virus Epidemic. Canadian Liver Journal 1, no. 4 (2018): 218-30.
Khan, Sarwat, Annie Bernier, Dustin Dapp, Emmanuel Fortier, Mel Krajden, Alexandra King, Jason Grebely, et al. 6th Canadian Symposium on Hepatitis C Virus: Delivering a Cure for Hepatitis C Infection—What Are the Remaining Gaps?. Canadian Liver Journal 1, no. 2 (2018):
Khan, S. T., W. Karges, C. L. Cooper, and A. M. Crawley. Hepatitis C Virus Core Protein Reduces Cd8(+) T-Cell Proliferation, Perforin Production and Degranulation but Increases Stat5 Activation. Immunology 154, no. 1 (May 2018): 156-65.
Janjua, N. Z., N. Islam, M. Kuo, A. Yu, S. Wong, Z. A. Butt, M. Gilbert, et al. Identifying Injection Drug Use and Estimating Population Size of People Who Inject Drugs Using Healthcare Administrative Datasets. Int J Drug Policy 55 (May 2018): 31-39.
Høj, Stine Bordier, Nanor Minoyan, Andreea Adelina Artenie, Jason Grebely, and Julie Bruneau. The Role of Prevention Strategies in Achieving Hcv Elimination in Canada: What Are the Remaining Challenges?. Canadian Liver Journal 1, no. 2 (2018): 4-13.
Gidi, Y., S. Bayram, C. J. Ablenas, A. S. Blum, and G. Cosa. Efficient One-Step Peg-Silane Passivation of Glass Surfaces for Single-Molecule Fluorescence Studies. ACS Appl Mater Interfaces 10, no. 46 (Nov 21 2018): 39505-11
Fayed, Sadeem T, Alexandra King, Malcolm King, Chris Macklin, Jessica Demeria, Norma Rabbitskin, Bonnie Healy, and Stewart Gonzales. In the Eyes of Indigenous People in Canada: Exposing the Underlying Colonial Etiology of Hepatitis C and the Imperative for Trauma-Informed Care. Canadian Liver Journal 1, no. 3 (2018): 115-29.
Fabre, T., M. F. Molina, G. Soucy, J. P. Goulet, B. Willems, J. P. Villeneuve, M. Bilodeau, and N. H. Shoukry. Type 3 Cytokines Il-17a and Il-22 Drive Tgf-Beta-Dependent Liver Fibrosis. Sci Immunol 3, no. 28 (Oct 26 2018)
Erman, A., A. Sathya, A. Nam, J. M. Bielecki, J. J. Feld, H. H. Thein, W. W. L. Wong, P. Grootendorst, and M. D. Krahn. Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis. J Viral Hepat 25, no. 5 (May 2018): 502-13.
Eller, C., L. Heydmann, C. C. Colpitts, E. R. Verrier, C. Schuster, and T. F. Baumert. The Functional Role of Sodium Taurocholate Cotransporting Polypeptide Ntcp in the Life Cycle of Hepatitis B, C and D Viruses. Cell Mol Life Sci 75, no. 21 (Nov 2018): 3895-905.
Darvishian, M., N. Z. Janjua, M. Chong, D. Cook, H. Samji, Z. A. Butt, A. Yu, et al. Estimating the Impact of Early Hepatitis C Virus Clearance on Hepatocellular Carcinoma Risk. J Viral Hepat 25, no. 12 (Dec 2018): 1481-92.
Cunningham, E. B., B. Hajarizadeh, J. Amin, N. Bretana, G. J. Dore, L. Degenhardt, S. Larney, et al. Longitudinal Injecting Risk Behaviours among People with a History of Injecting Drug Use in an Australian Prison Setting: The Hits-P Study. Int J Drug Policy 54 (Apr 2018): 18-25.
Colpitts, C. C., R. G. Tawar, L. Mailly, C. Thumann, L. Heydmann, S. C. Durand, F. Xiao, et al. Humanisation of a Claudin-1-Specific Monoclonal Antibody for Clinical Prevention and Cure of Hcv Infection without Escape. Gut 67, no. 4 (Apr 2018): 736-45.
Christina Greenaway MD, MSc1, 2, Iuliia Makarenko MSc1, Fozia Tanveer3, and PhD4 Naveed Z Janjua MD, 5. Addressing Hepatitis C in the Foreign-Born Population: A Key to Hepatitis C Virus Elimination in Canada. Canadian Liver Journal 1, no. 2 (2018): 34-50.
Cheng, Michael L, Mohamed S Abdel-Hakeem, Sophie E Cousineau, Jason Grebely, Alison D Marshall, Sahar Saeed, Selena M Sagan, et al. The 7th Canadian Symposium on Hepatitis C Virus: “Toward Elimination of Hcv: How to Get There”. Canadian Liver Journal 1, no. 3 (2018): 139-52.
Chan, Justin, Jim Young, Joseph Cox, Roy Nitulescu, and Marina B Klein. Patterns of Practice and Barriers to Care for Hepatitis C in the Direct-Acting Antiviral (Daa) Era: A National Survey of Canadian Infectious Diseases Physicians. Canadian Liver Journal 1, no. 4 (2018): 231-39.
Bernier, A., and S. M. Sagan. The Diverse Roles of Micrornas at the Host(-)Virus Interface. Viruses 10, no. 8 (Aug 19 2018).
Amador-Canizares, Y., M. Panigrahi, A. Huys, R. D. Kunden, H. M. Adams, M. J. Schinold, and J. A. Wilson. Mir-122, Small Rna Annealing and Sequence Mutations Alter the Predicted Structure of the Hepatitis C Virus 5' Utr Rna to Stabilize and Promote Viral Rna Accumulation. Nucleic Acids Res 46, no. 18 (Oct 12 2018): 9776-92.
Amador-Canizares, Y., A. Bernier, J. A. Wilson, and S. M. Sagan. Mir-122 Does Not Impact Recognition of the Hcv Genome by Innate Sensors of Rna but Rather Protects the 5' End from the Cellular Pyrophosphatases, Dom3z and Dusp11. Nucleic Acids Res 46, no. 10 (Jun 1 2018): 5139-58.
Alimohammadi, Arshia, Julie Holeksa, Robyn Parsons, Rossita Yung, Neilofar Amiri, David Truong, and Brian Conway. Diagnosis and Treatment of Hepatitis C Virus Infection: A Tool for Engagement with People Who Inject Drugs in Vancouver’s Downtown Eastside. Canadian Liver Journal 1, no. 2 (2018): 14-33.
Alimohammadi, A., J. Holeksa, A. Thiam, D. Truong, and B. Conway. Real-World Efficacy of Direct-Acting Antiviral Therapy for Hcv Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary Setting. Open Forum Infect Dis 5, no. 6 (Jun 2018): ofy120.
2017
Wu, Q., Z. Li, P. Mellor, Y. Zhou, D. H. Anderson, and Q. Liu. The Role of Pten - Hcv Core Interaction in Hepatitis C Virus Replication. Sci Rep 7, no. 1 (Jun 16 2017): 3695.
Wu, Q., Z. Li, and Q. Liu. Treatment with Pten-Long Protein Inhibits Hepatitis C Virus Replication. Virology 511 (Nov 2017): 1-8.
Sarhan, M. A., M. S. Abdel-Hakeem, A. L. Mason, D. L. Tyrrell, and M. Houghton. Glycogen Synthase Kinase 3beta Inhibitors Prevent Hepatitis C Virus Release/Assembly through Perturbation of Lipid Metabolism. Sci Rep 7, no. 1 (May 31 2017): 2495.
Puzhko, S., E. Roy, D. Jutras-Aswad, A. A. Artenie, E. Fortier, G. Zang, and J. Bruneau. High Hepatitis C Incidence in Relation to Prescription Opioid Injection and Poly-Drug Use: Assessing Barriers to Hepatitis C Prevention. Int J Drug Policy 47 (Sep 2017): 61-68.
Moqueet, N., C. Kanagaratham, M. J. Gill, M. Hull, S. Walmsley, D. Radzioch, S. Saeed, R. W. Platt, and M. B. Klein. A Prognostic Model for Development of Significant Liver Fibrosis in Hiv-Hepatitis C Co-Infection. PLoS One 12, no. 5 (2017): e0176282.
Marshall, A. D., J. Grebely, G. J. Dore, and C. Treloar. 'I Didn't Want to Let It Go Too Far.' The Decisions and Experiences of People Who Inject Drugs Who Received a Liver Disease Assessment as Part of a Liver Health Promotion Campaign: The Liverlife Study. Int J Drug Policy 47 (Sep 2017): 153-60.
Larney, S., A. Peacock, J. Leung, S. Colledge, M. Hickman, P. Vickerman, J. Grebely, et al. Global, Regional, and Country-Level Coverage of Interventions to Prevent and Manage Hiv and Hepatitis C among People Who Inject Drugs: A Systematic Review. Lancet Glob Health 5, no. 12 (Dec 2017): e1208-e20.
Hyrina, A., A. D. Olmstead, P. Steven, M. Krajden, E. Tam, and F. Jean. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among Three Important Molecular Players in Lipid Homeostasis: Circulating Microrna (Mir)-24, Mir-223, and Proprotein Convertase Subtilisin/Kexin Type 9. EBioMedicine 23 (Sep 2017): 68-78.
Hyrina, A., F. Meng, S. J. McArthur, S. Eivemark, I. R. Nabi, and F. Jean. Human Subtilisin Kexin Isozyme-1 (Ski-1)/Site-1 Protease (S1p) Regulates Cytoplasmic Lipid Droplet Abundance: A Potential Target for Indirect-Acting Anti-Dengue Virus Agents. PLoS One 12, no. 3 (2017):
Hart, K. M., T. Fabre, J. C. Sciurba, R. L. Gieseck, 3rd, L. A. Borthwick, K. M. Vannella, T. H. Acciani, et al. Type 2 Immunity Is Protective in Metabolic Disease but Exacerbates Nafld Collaboratively with Tgf-Beta. Sci Transl Med 9, no. 396 (Jun 28 2017).
Fahmy, A. M., and P. Labonte. The Autophagy Elongation Complex (Atg5-12/16l1) Positively Regulates Hcv Replication and Is Required for Wild-Type Membranous Web Formation. Sci Rep 7 (Jan 9 2017): 40351.
Degenhardt, L., A. Peacock, S. Colledge, J. Leung, J. Grebely, P. Vickerman, J. Stone, et al. Global Prevalence of Injecting Drug Use and Sociodemographic Characteristics and Prevalence of Hiv, Hbv, and Hcv in People Who Inject Drugs: A Multistage Systematic Review. Lancet Glob Health 5, no. 12 (Dec 2017): e1192-e207.
Cunningham, E. B., B. Hajarizadeh, N. A. Bretana, J. Amin, B. Betz-Stablein, G. J. Dore, F. Luciani, et al. Ongoing Incident Hepatitis C Virus Infection among People with a History of Injecting Drug Use in an Australian Prison Setting, 2005-2014: The Hits-P Study. J Viral Hepat 24, no. 9 (Sep 2017): 733-41.
Colpitts, C. C., R. T. Chung, and T. F. Baumert. Entry Inhibitors: A Perspective for Prevention of Hepatitis C Virus Infection in Organ Transplantation. ACS Infect Dis 3, no. 9 (Sep 8 2017): 620-23.
Bajis, S., G. J. Dore, B. Hajarizadeh, E. B. Cunningham, L. Maher, and J. Grebely. Interventions to Enhance Testing, Linkage to Care and Treatment Uptake for Hepatitis C Virus Infection among People Who Inject Drugs: A Systematic Review. Int J Drug Policy 47 (Sep 2017): 34-46.
Artenie, A. A., G. Zang, M. Daniel, E. Fortier, D. Jutras-Aswad, S. Puzhko, and J. Bruneau. Short-Term Injection Drug Use Changes Following Hepatitis C Virus (Hcv) Assessment and Treatment among Persons Who Inject Drugs with Acute Hcv Infection. Int J Drug Policy 47 (Sep 2017): 239-43.
Saeed S, Strumpf EC, Moodie EE, Young J, Nitulescu R, Cox J, Wong A, Walmsely S, Cooper C, Vachon ML, Martel-Laferriere V, Hull M, Conway B, Klein MB; Canadian Co-Infection Cohort Study. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada. J Int AIDS Soc. 2017 Nov;20(3).
MacParland SA, Tsoi KM, Ouyang B, Ma XZ, Manuel J, Fawaz A, Ostrowski MA, Alman BA, Zilman A, Chan WC, McGilvray ID. Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood. ACS Nano. 2017 Mar 28;11(3):2428-2443.
Colpitts CC and Baumert TF. SMAD about hepatitis C virus cell entry and liver disease. Gastroenterology. 2017 Jan; 152(1):21-23.
Colpitts CC and Baumert TF. Claudins in viral infection: from entry to spread. Pflugers Arch. 2017 Jan;469(1):27-34
Abdel-Hakeem MS, Boisvert M, Bruneau J, Soudeyns H, Shoukry NH. Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance. PLoS Pathog. 2017 Feb 1;13(2):e1006191.
Ablenas CJ, Liu HW, Shkriabai N, Kvaratskhelia M, Cosa G, Götte M. Dynamic Interconversions of HCV Helicase Binding Modes on the Nucleic Acid Substrate. ACS Infect Dis. 2017 Jan 13;3(1):99-109.
2016
Verrier, E. R., C. C. Colpitts, C. Schuster, M. B. Zeisel, and T. F. Baumert. Cell Culture Models for the Investigation of Hepatitis B and D Virus Infection. Viruses 8, no. 9 (Sep 20 2016).
Kirkegaard, K., N. J. van Buuren, and R. Mateo. My Cousin, My Enemy: Quasispecies Suppression of Drug Resistance. Curr Opin Virol 20 (Oct 2016): 106-11.
Corsi, D. J., W. Karges, K. Thavorn, A. M. Crawley, and C. L. Cooper. Influence of Female Sex on Hepatitis C Virus Infection Progression and Treatment Outcomes. Eur J Gastroenterol Hepatol 28, no. 4 (Apr 2016): 405-11
Moqueet, N., C. Cooper, J. Gill, M. Hull, R. W. Platt, and M. B. Klein. Responder Interferon Lambda Genotypes Are Associated with Higher Risk of Liver Fibrosis in Hiv-Hepatitis C Virus Coinfection. J Infect Dis 214, no. 1 (Jul 1 2016): 80-6.
Saeed, S., E. C. Strumpf, S. L. Walmsley, K. Rollet-Kurhajec, N. Pick, V. Martel-Laferriere, M. Hull, et al. How Generalizable Are the Results from Trials of Direct Antiviral Agents to People Coinfected with Hiv/Hcv in the Real World? Clin Infect Dis 62, no. 7 (Apr 1 2016): 919-26.
Kulkarni, A. S., M. J. Damha, R. F. Schinazi, H. Mo, B. Doehle, S. M. Sagan, and M. Gotte. A Complex Network of Interactions between S282 and G283 of Hepatitis C Virus Nonstructural Protein 5b and the Template Strand Affects Susceptibility to Sofosbuvir and Ribavirin. Antimicrob Agents Chemother 60, no. 4 (Apr 2016): 2018-27.
Depla, M., S. Pelletier, N. Bedard, C. Brunaud, J. Bruneau, and N. H. Shoukry. Ifn-Lambda3 Polymorphism Indirectly Influences Nk Cell Phenotype and Function During Acute Hcv Infection. Immun Inflamm Dis 4, no. 3 (Sep 2016): 376-88
Saeed S, Strumpf EC, Walmsley SL, Rollet-Kurhajec K, Pick N, Martel-Laferrière V, Hull M, Gill MJ, Cox J, Cooper C, Klein MB; Canadian Co-Infection Cohort Study. How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World? Clin Infect Dis. 2016 Apr 1;62(7):919-26.
Strmiskova M, Desrochers GF, Shaw TA, Powdrill MH, Lafreniere MA, Pezacki JP. Chemical Methods for Probing Virus-Host Proteomic Interactions. ACS Infect Dis. 2016 Nov 11;2(11):773-786.
Lafreniere MA, Powdrill MH, Singaravelu R, Pezacki JP. 6-Hydroxydopamine Inhibits the Hepatitis C Virus through Alkylation of Host and Viral Proteins and the Induction of Oxidative Stress. ACS Infect Dis. 2016 Nov 11;2(11):863-871.
Powdrill MH, Desrochers GF, Singaravelu R, Pezacki JP. The role of microRNAs in metabolic interactions between viruses and their hosts. Curr Opin Virol. 2016 Aug;19:71-6.
Tsoi, K.M., MacParland, S.A., Spetzler, V.N., Ma, X.Z., Fadel, S.M., Sykes, E.A., Conneely, J.B., Alman, B., Selzner, M., Ostrowski, M.A., Adeyi, O.A., Zilman, A., McGilvray, I.D. and Chan, W.C.W. The mechanism of nanomaterial uptake by the liver. Nat Mater. 2016 Nov; 15(11): 1212–1221.
MacParland SA, Fadel SM, Mihajlovic V, Fawaz A, Kim C, Rahman AK, Liu J, Kaul R, Kovacs C, Grebely J, Dore GJ, Wong DK, Ostrowski MA. HCV Specific IL-21 Producing T Cells but Not IL-17A Producing T Cells Are Associated with HCV Viral Control in HIV/HCV Coinfection. PLoS One. 2016 Apr 28;11(4):e0154433.
MacParland SA, Ma XZ, Chen L, Khattar R, Cherepanov V, Selzner M, Feld JJ, Selzner N, McGilvray ID. Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. J Virol. 2016 May 27;90(12):5549-60.
Colpitts CC and Baumert TF. Cell surface glycans as viral entry factors and antiviral targets. Recent Advances in Biotechnology. 2016; 3:39-59. Bentham Science
Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB and Baumert TF. Solute carrier NTCP regulates innate antiviral immune responses targeting hepatitis C virus infection of hepatocytes. Cell Reports. 2016 Oct; 17:1357-1368.
Boisvert M, Zhang W, Elrod EJ, Bernard NF, Villeneuve JP, Bruneau J, Marcotrigiano J, Shoukry NH, Grakoui A. Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells. J Immunol. 2016 Dec 15;197(12):4848-4858.
Boisvert M, Shoukry NH. Type III Interferons in Hepatitis C Virus Infection. Front Immunol. 2016 Dec 23;7:628.
Kofahi HM, Taylor NG, Hirasawa K, Grant MD, Russell RS. Hepatitis C Virus Infection of Cultured Human Hepatoma Cells Causes Apoptosis and Pyroptosis in Both Infected and Bystander Cells. Sci Rep. 2016 Dec 15;6:37433.
Murira A, Lamarre A. Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Front Immunol. 2016 Dec 19;7:609.
Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, Shoukry NH, Taylor LE, Grebely J; the Canadian Network on Hepatitis C (CanHepC). Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ OPEN October 14, 2016 vol. 4no. 4 E605-E614.
van Buuren N, Fradette L, Grebely J, King A, Krajden M, MacParland S, Marshall A, Saeed S, Wilson J, Klein MB, and Sagan SM. The 5th Canadian Symposium on Hepatitis C Virus: We’re Not Done Yet: Remaining Challenges in Hepatitis C. Can J Gastroenterol, vol. 2016:7603526. Epub 2016 Oct 24.
Sagan SM, Dupont B, Grebely J, Krajden M, MacParland SA, Raven JF, Saeed S, Feld JJ, Tyrrell LD, Wilson JA. Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Can J Gastroenterol, Vol 2016 (2016), Article ID 5743521.
2015
Thibault, P. A., A. Huys, Y. Amador-Canizares, J. E. Gailius, D. E. Pinel, and J. A. Wilson. Regulation of Hepatitis C Virus Genome Replication by Xrn1 and Microrna-122 Binding to Individual Sites in the 5' Untranslated Region. J Virol 89, no. 12 (Jun 2015): 6294-311.
MacParland SA, Corkum CP, Burgess C, Karwowska S, Kroll W, Michalak TI. Differential expression of interferon alpha inducible genes in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus and healthy donors. Int Immunopharmacol. 2015 Apr;25(2):545-52.
MacParland SA, Chen AY, Corkum CP, Pham TN, Michalak TI. Patient-derived hepatitis C virus inhibits CD4⁺ but not CD8⁺ T lymphocyte proliferation in primary T cells. Virol J. 2015 Jun 19;12:93.
Singaravelu R, O'Hara S, Jones DM, Chen R, Taylor NG, et al. MicroRNAs regulate the immunometabolic response to viral infection in the liver. Nat Chem Biol. 2015 Dec;11(12):988-93.
Fortier E, Alavi M, Micallef M, Dunlop AJ, Balcomb AC, et al. The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. Int J Drug Policy. 2015 Nov;26(11):1094-102.
Marshall AD, Micallef M, Erratt A, Telenta J, Treloar C, et al. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study. Int J Drug Policy. 2015 Oct;26(10):984-91.
Artenie AA, Jutras-Aswad D, Roy É, Zang G, Bamvita JM, et al. Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement. J Viral Hepat. 2015 Oct;22(10):792-9.
Artenie AA, Roy É, Zang G, Jutras-Aswad D, Bamvita JM, et al. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention. Int J Drug Policy. 2015 Oct;26(10):970-5.
Artenie AA, Bruneau J, Roy É, Zang G, Lespérance F, et al. Licit and illicit substance use among people who inject drugs and the association with subsequent suicidal attempt. Addiction. 2015 Oct;110(10):1636-43
Olmstead AD, Joy JB, Montoya V, Luo I, Poon AF, et al. A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events. Infect Genet Evol. 2015 Jul;33:101-9.
Cunningham EB, Jacka B, DeBeck K, Applegate TL, Harrigan PR, et al. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug Alcohol Depend. 2015 Jul 1;152:272-6.
Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs--impact on therapy. Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):218-30.
Moqueet N, Infante-Rivard C, Platt RW, Young J, Cooper C, et al. Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals. Int J Mol Sci. 2015 Mar 20;16(3):6496-512.
Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology. 2015 Mar;477:1-9.
Artenie AA, Bruneau J, Zang G, Lespérance F, Renaud J, et al. Associations of substance use patterns with attempted suicide among persons who inject drugs: can distinct use patterns play a role?. Drug Alcohol Depend. 2015 Feb 1;147:208-14.
2014
Wong JA, Bhat R, Hockman D, Logan M, Chen C, et al. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol. 2014 Dec;88(24):14278-88.
Burles K, van Buuren N, Barry M. Ectromelia virus encodes a family of Ankyrin/F-box proteins that regulate NFκB. Virology. 2014 Nov;468-470:351-62.
Jacka B, Applegate T, Krajden M, Olmstead A, Harrigan PR, et al. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology. 2014 Nov;60(5):1571-80.
Nasheri N, McKay CS, Fulton K, Twine S, Powdrill MH, et al. Hydrophobic triaryl-substituted β-lactams as activity-based probes for profiling eukaryotic enzymes and host-pathogen interactions. Chembiochem. 2014 Oct 13;15(15):2195-200.
Artenie AA, Bruneau J, Lévesque A, Wansuanganyi JM. Role of primary care providers in hepatitis C prevention and care: one step away from evidence-based practice. Can Fam Physician. 2014 Oct;60(10):881-2, e468-70.
Abdel-Hakeem MS, Bédard N, Murphy D, Bruneau J, Shoukry NH. Signatures of protective memory immune responses during hepatitis C virus reinfection. Gastroenterology. 2014 Oct;147(4):870-881.e8.
MacParland SA, Bilodeau M, Grebely J, Bruneau J, Cooper C, et al. The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. Can J Gastroenterol Hepatol. 2014 Oct;28(9):481-7.
van Buuren N, Burles K, Schriewer J, Mehta N, Parker S, et al. EVM005: an ectromelia-encoded protein with dual roles in NF-κB inhibition and virulence. PLoS Pathog. 2014 Aug;10(8):e1004326.
Atoom AM, Taylor NG, Russell RS. The elusive function of the hepatitis C virus p7 protein. Virology. 2014 Aug;462-463:377-87.
Singaravelu R, Delcorde J, Lyn RK, Steenbergen RH, Jones DM, et al. Investigating the antiviral role of cell death-inducing DFF45-like effector B in HCV replication. FEBS J. 2014 Aug;281(16):3751-65.
Sherratt AR, Nasheri N, McKay CS, O'Hara S, Hunt A, et al. A new chemical probe for phosphatidylinositol kinase activity. Chembiochem. 2014 Jun 16;15(9):1253-6.
Karam P, Powdrill MH, Liu HW, Vasquez C, Mah W, et al. Dynamics of hepatitis C virus (HCV) RNA-dependent RNA polymerase NS5B in complex with RNA. J Biol Chem. 2014 May 16;289(20):14399-411.
Lyn RK, Singaravelu R, Kargman S, O'Hara S, Chan H, et al. Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes. Sci Rep. 2014 Apr 1;4:4549
Holder KA, Russell RS, Grant MD. Natural killer cell function and dysfunction in hepatitis C virus infection. Biomed Res Int. 2014;2014:903764.
Bamvita JM, Roy E, Zang G, Jutras-Aswad D, Artenie AA, et al. Portraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysis. Hepat Res Treat. 2014;2014:631481. [PubMed] Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274.
Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014 Jun 16;5:274.
Singaravelu R, Chen R, Lyn RK, Jones DM, O'Hara S, et al. Hepatitis C virus induced up-regulation of microRNA-27: a novel mechanism for hepatic steatosis. Hepatology. 2014 Jan;59(1):98-108.
2013
Steenbergen RH, Joyce MA, Thomas BS, Jones D, Law J, et al. Human serum leads to differentiation of human hepatoma cells, restoration of very-low-density lipoprotein secretion, and a 1000-fold increase in HCV Japanese fulminant hepatitis type 1 titers. Hepatology. 2013 Dec;58(6):1907-17.
Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, et al. The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol. 2013 Nov;27(11):627-32
Holder KA, Stapleton SN, Gallant ME, Russell RS, Grant MD. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions. J Immunol. 2013 Sep 15;191(6):3308-18.
Thibault PA, Wilson JA. Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res. 2013 Sep; 75:48-59. PMID: 23541631.
Atoom AM, Jones DM, Russell RS. Evidence suggesting that HCV p7 protects E2 glycoprotein from premature degradation during virus production. Virus Res. 2013 Sep;176(1-2):199-210.
Sagan SM, Sarnow P, Wilson JA. Modulation of GB virus B RNA abundance by microRNA-122: dependence on and escape from microRNA-122 restriction. J Virol. 2013 Jul;87(13):7338-47.
Pelletier S, Bédard N, Said E, Ancuta P, Bruneau J, et al. Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. J Virol. 2013 Jun;87(12):6769-81.
Deans GD, Raffa JD, Lai C, Fischer B, Krajden M, et al. Mortality in a large community-based cohort of inner-city residents in Vancouver, Canada. CMAJ Open. 2013 May; 1(2):E68-76.
Nasheri N, Joyce M, Rouleau Y, Yang P, Yao S, et al. Modulation of fatty acid synthase enzyme activity and expression during hepatitis C virus replication. Chem Biol. 2013 Apr 18;20(4):570-82.
Thibault PA, Huys A, Dhillon P, Wilson JA. MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells. Virology. 2013 Feb 5;436(1):179-90.
Law JL, Chen C, Wong J, Hockman D, Santer DM, et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One. 2013;8(3):e59776.
Huys A, Thibault PA, Wilson JA. Modulation of hepatitis C virus RNA accumulation and translation by DDX6 and miR-122 are mediated by separate mechanisms. PLoS One. 2013;8(6):e67437.
Mazumder N, Lyn RK, Singaravelu R, Ridsdale A, Moffatt DJ, et al. Fluorescence lifetime imaging of alterations to cellular metabolism by domain 2 of the hepatitis C virus core protein. PLoS One. 2013;8(6):e66738.
Sarhan MA, Chen AY, Michalak TI. Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus. PLoS One. 2013;8(4):e62159
Nasheri N, Pezacki JP, Sagan SM. Design and screening of siRNAs against highly structured RNA targets. Methods Mol Biol. 2013;942:69-86.
Weaver A, Menard D, Cabrera C, Taylor A. Embodying the moral code: Thirty years of final girls in slasher films. Psychology of Popular Media Culture. 2013.
2012
Machlin ES, Sarnow P, Sagan SM. Combating hepatitis C virus by targeting microRNA-122 using locked nucleic acids. Curr Gene Ther. 2012 Aug;12(4):301-6.
Singaravelu R, Nasheri N, Sherratt A, Pezacki JP. Systems biology methods help develop a better understanding of hepatitis C virus-induced liver injury. Hepatology. 2012 Jul;56(1):1-4.
Sarhan MA, Pham TN, Chen AY, Michalak TI. Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J Virol. 2012 Apr;86(7):3723-35.
Blais DR, Nasheri N, McKay CS, Legault MC, Pezacki JP. Activity-based protein profiling of host-virus interactions. Trends Biotechnol. 2012 Feb;30(2):89-99.
Beq S, Rozlan S, Pelletier S, Willems B, Bruneau J, et al. Altered thymic function during interferon therapy in HCV-infected patients. PLoS One. 2012;7(4):e34326.
Kneteman NM, Asthana S, Lewis J, Dibben C, Douglas D, et al. Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection. Liver Transpl. 2012 Jan;18(1):38-44.
Sakhdari A, Mujib S, Vali B, Yue FY, MacParland S, et al. Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection. PLoS One. 2012;7(7):e40146.
Cabrera C, & Menard AD. She exploded into a million pieces: A multi-method examination of orgasm descriptions in contemporary romance novels. Sexuality and Culture, 2012,16,4.
Zachariades F & Cabrera C. The duty to warn revisited: Contemporary issues in the North American context. Journal of Ethics in Mental Health, 2012, 7,1. Zachariades F & Cabrera C. The duty to warn revisited: Contemporary issues in the North American context. Journal of Ethics in Mental Health, 2012, 7,1.
Zhang C, Huys A, Thibault PA, Wilson JA. Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. Virology. 2012 Nov 25;433(2):479-88.
Sarhan MA, Chen AY, Russell RS, Michalak TI. Patient-derived hepatitis C virus and JFH-1 clones differ in their ability to infect human hepatoma cells and lymphocytes. J Gen Virol. 2012 Nov;93(Pt 11):2399-407.
John-Baptiste A, Yeung MW, Leung V, van der Velde G, Krahn M. Cost effectiveness of hepatitis C-related interventions targeting substance users and other high-risk groups: a systematic review. Pharmacoeconomics. 2012 Nov 1;30(11):1015-34.
Pattullo V, Thein HH, Heathcote EJ, Guindi M. Combining semiquantitative measures of fibrosis and qualitative features of parenchymal remodelling to identify fibrosis regression in hepatitis C: a multiple biopsy study. Histopathology. 2012 Sep;61(3):473-87.
2011
Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, et al. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20509-13.
Shi J, Zhou L, Zhang H, McBrayer TR, Detorio MA, et al. Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-7-deazapurine nucleosides, their phosphoramidate prodrugs and 5'-triphosphates. Bioorg Med Chem Lett. 2011 Dec 1;21(23):7094-8
Jones DM, Atoom AM, Zhang X, Kottilil S, Russell RS. A genetic interaction between the core and NS3 proteins of hepatitis C virus is essential for production of infectious virus. J Virol. 2011 Dec;85(23):12351-61
Shoukry NH, Pelletier S, Chang KM. A view to natural killer cells in hepatitis C. Gastroenterology. 2011 Oct;141(4):1144-8.
Cheng J, Danielson DC, Nasheri N, Singaravelu R, Pezacki JP. Enhanced specificity of the viral suppressor of RNA silencing protein p19 toward sequestering of human microRNA-122. Biochemistry. 2011 Sep 13;50(36):7745-55.
Berke JM, Vijgen L, Lachau-Durand S, Powdrill MH, Rawe S, et al. Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2011 Aug;55(8):3812-20.
Nasheri N, Cheng J, Singaravelu R, Wu P, McDermott MT, et al. An enzyme-linked assay for the rapid quantification of microRNAs based on the viral suppressor of RNA silencing protein p19. Anal Biochem. 2011 May 15;412(2):165-72.
Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, et al. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol. 2011 May;85(9):4386-98.
Matthews GV, Pham ST, Hellard M, Grebely J, Zhang L, et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis. 2011 Mar 15;52(6):803-11.
Pezacki JP, Blake JA, Danielson DC, Kennedy DC, Lyn RK, et al. Chemical contrast for imaging living systems: molecular vibrations drive CARS microscopy. Nat Chem Biol. 2011 Mar;7(3):137-45.
Machlin ES, Sarnow P, Sagan SM. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3193-8
Nasheri N, Singaravelu R, Goodmurphy M, Lyn RK, Pezacki JP. Competing roles of microRNA-122 recognition elements in hepatitis C virus RNA. Virology. 2011 Feb 20;410(2):336-44.
Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. J Viral Hepat. 2011 Jan;18(1):32-41.
Vali B, Tohn R, Cohen MJ, Sakhdari A, Sheth PM, et al. Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses. J Virol. 2011 Jan;85(1):254-63
Menard, A.D. & Cabrera, C. Whatever the approach, Tab B still fits into slot A: Twenty years of sex scripts in romance novels. Sexuality and Culture, 2011, 15, 1. Menard, A.D. & Cabrera, C. Whatever the approach, Tab B still fits into slot A: Twenty years of sex scripts in romance novels. Sexuality and Culture, 2011, 15, 1.
MacParland SA, Vail B, and Ostrowski M. The immunopathogenesis of HIV/Hepatitis C virus coinfection. Future Virology 2011; 6, 1115-1128.
2010
Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology. 2010 Jan;138(1):123-35.e1-2.
Liao PC, Ng LT, Lin LT, Richardson CD, Wang GH, et al. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med Food. 2010 Dec;13(6):1415-23.
Grebely J, Matthews GV, Petoumenos K, Dore GJ. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. J Viral Hepat. 2010 Dec;17(12):896.
Ma XZ, Bartczak A, Zhang J, Khattar R, Chen L, et al. Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome. J Virol. 2010 Dec;84(23):12419-28.
Pelletier S, Drouin C, Bédard N, Khakoo SI, Bruneau J, et al. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. J Hepatol. 2010 Nov;53(5):805-16.
Powdrill MH, Bernatchez JA, Götte M. Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B. Viruses. 2010 Oct;2(10):2169-95.
Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010 Oct;52(4):1216-24.
Steenbergen RH, Joyce MA, Lund G, Lewis J, Chen R, et al. Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success. Am J Physiol Gastrointest Liver Physiol. 2010 Oct;299(4):G844-54
Abdel-Hakeem MS, Bédard N, Badr G, Ostrowski M, Sékaly RP, et al. Comparison of immune restoration in early versus late alpha interferon therapy against hepatitis C virus. J Virol. 2010 Oct;84(19):10429-35.
Vivithanaporn P, Maingat F, Lin LT, Na H, Richardson CD, et al. Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PLoS One. 2010 Sep 21;5(9):e12856.
Vali B, Jones RB, Sakhdari A, Sheth PM, Clayton K, et al. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol. 2010 Sep;40(9):2493-505.
Gujar SA, Jenkins AK, Macparland SA, Michalak TI. Pre-acute hepadnaviral infection is associated with activation-induced apoptotic death of lymphocytes in the woodchuck (Marmota monax) model of hepatitis B. Dev Comp Immunol. 2010 Sep;34(9):999-1008.
Lin LT, Noyce RS, Pham TN, Wilson JA, Sisson GR, et al. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J Virol. 2010 Sep;84(18):9170-80.
Zhao L, Shields J, Tyrrell DL. Functional changes, increased apoptosis, and diminished nuclear factor-kappaB activity of myeloid dendritic cells during chronic hepatitis C infection. Hum Immunol. 2010 Aug;71(8):751-62.
Kawahara T, Toso C, Douglas DN, Nourbakhsh M, Lewis JT, et al. Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model. Liver Transpl. 2010 Aug;16(8):974-82.
John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol. 2010 Aug;53(2):245-51.
Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol. 2010 Jul;25(7):1281-4.
Lin LT, Dawson PW, Richardson CD. Viral interactions with macroautophagy: a double-edged sword. Virology. 2010 Jun 20;402(1):1-10.
Sagan SM, Nasheri N, Luebbert C, Pezacki JP. The efficacy of siRNAs against hepatitis C virus is strongly influenced by structure and target site accessibility. Chem Biol. 2010 May 28; 17(5):515-27.
Sagan SM, Sarnow P. Plasmacytoid dendritic cells as guardians in hepatitis C virus-infected liver. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7625-6.
Powdrill MH, Deval J, Narjes F, De Francesco R, Götte M. Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines. Antimicrob Agents Chemother. 2010 Mar;54(3):977-83.
Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7.
Grebely J, Petoumenos K, Matthews GV, Haber P, Marks P, et al. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Drug Alcohol Depend. 2010 Mar 1;107(2-3):244-9
Chen L, Borozan I, Sun J, Guindi M, Fischer S, et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology. 2010 Mar;138(3):1123-33.e1-3.
Chen L, Sun J, Meng L, Heathcote J, Edwards AM, et al. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol. 2010 Feb;91(Pt 2):382-8.
Mohajerani SA, Nourbakhsh M, Cadili A, Lakey JR, Kneteman NM. Transplant of Primary Human Hepatocytes Cocultured With Bone Marrow Stromal Cells to SCID Alb-uPA Mice. Cell Med. 2010;1(2):81-92.
2009
Godin-Ethier J, Pelletier S, Hanafi LA, Gannon PO, Forget MA, et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol. 2009 Dec 15;183(12):7752-60.
Lyn RK, Kennedy DC, Sagan SM, Blais DR, Rouleau Y, et al. Direct imaging of the disruption of hepatitis C virus replication complexes by inhibitors of lipid metabolism. Virology. 2009 Nov 10;394(1):130-42.
Thein HH, Yi Q, Heathcote EJ, Krahn MD. Prognosis of hepatitis C virus-infected Canadian post-transfusion compensation claimant cohort. J Viral Hepat. 2009 Nov;16(11):802-13.
Selzner M, Selzner N, Chen L, Borozan I, Sun J, et al. Exaggerated up-regulation of tumor necrosis factor alpha-dependent apoptosis in the older mouse liver following reperfusion injury: targeting liver protective strategies to patient age. Liver Transpl. 2009 Nov;15(11):1594-604.
John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009 Oct;104(10):2439-48.
Grebely J, Thomas DL, Dore GJ. HCV reinfection studies and the door to vaccine development. J Hepatol. 2009 Oct;51(4):628-31.
Chong CA, Li S, Nguyen GC, Sutton A, Levy MH, et al. Health-state utilities in a prisoner population: a cross-sectional survey. Health Qual Life Outcomes. 2009 Aug 28;7:78.
Cheng J, Koukiekolo R, Kieliszkiewicz K, Sagan SM, Pezacki JP. Cysteine residues of Carnation Italian Ringspot virus p19 suppressor of RNA silencing maintain global structural integrity and stability for siRNA binding. Biochim Biophys Acta. 2009 Aug;1794(8):1197-203.
Koukiekolo R, Jakubek ZJ, Cheng J, Sagan SM, Pezacki JP. Studies of a viral suppressor of RNA silencing p19-CFP fusion protein: a FRET-based probe for sensing double-stranded fluorophore tagged small RNAs. Biophys Chem. 2009 Aug;143(3):166-9.
John-Baptiste A, Varenbut M, Lingley M, Nedd-Roderique T, Teplin D, et al. Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat. 2009 Aug;16(8):557-67.
Seaman K, Paterson BL, Vallis M, Hirsch G, Peltekian KM. Future directions for investigation of fatigue in chronic hepatitis C viral infection. Chronic Illn. 2009 Jun;5(2):115-28.
Welbourn S, Jirasko V, Breton V, Reiss S, Penin F, et al. Investigation of a role for lysine residues in non-structural proteins 2 and 2/3 of the hepatitis C virus for their degradation and virus assembly. J Gen Virol. 2009 May;90(Pt 5):1071-80.
MacParland SA, Pham TN, Guy CS, Michalak TI. Hepatitis C virus persisting after clinically apparent sustained virological response to antiviral therapy retains infectivity in vitro. Hepatology. 2009 May;49(5):1431-41.
Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat. 2009 May;16(5):352-8.
Pezacki JP, Sagan SM, Tonary AM, Rouleau Y, Bélanger S, et al. Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus. BMC Chem Biol. 2009 Jan 16;9:2.
Conway B, Grebely J, Tossonian H, Lefebvre D, de Vlaming S. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S73-8.
Cabrera C, Miller D. The value of grades in graduate school. Psynopsis, Canada’s Psychology Newspaper, 2009, 31(3), 29.
Cabrera C, Saciragic L, Ethier J. Student perspectives of the multidisciplinary experience. Psynopsis, Canada’s Psychology Newspaper, 2009, 31(1), 26.
Thein HH, Dore GJ. Health-related quality of life in prisoners. Preedy VR, Watson RR (eds.) (2009) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York.
Welbourn S. and Pause A. The hepatitis C virus NS2/3 protease: A future antiviral drug target? Future Virology 4, 2009. pp. 463-472
